Stevenage, UK - 04 May 2020 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for schizophrenia, hearing loss and other serious brain disorders, today announced that a First-in-Human Phase I trial of AUT00201, a potent and selective modulator of Kv3 channels, is underway in the UK.
AUT00201, a new molecule, is a potent modulator of Kv3 ion channels, which are implicated in brain circuits believed to be dysfunctional in a variety of CNS disorders, including schizophrenia, hearing disorders, Fragile X and potentially other indications.
The first-in-human Phase I study initiated by Autifony is a randomized, placebo controlled ascending dose trial that is being conducted in the UK. It is investigating the safety, tolerability and pharmacokinetics of orally administered single and multiple doses of AUT00201 in healthy volunteers. The trial is well advanced but has been suspended temporarily in response to the COVID-19 pandemic.
Dr Charles Large, Chief Executive Officer of Autifony Therapeutics, commented: “We are delighted that Autifony now has a further molecule with great potential in clinical development. The progression of a number of candidate drug molecules into clinical evaluation puts us in a strong position to explore the full potential of the Kv3 mechanism in a variety of important diseases, including but not limited to schizophrenia and hearing disorders.”
About Autifony Therapeutics Ltd
Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat hearing disorders and other serious diseases of the central nervous system. It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc.
For more information please visit www.autifony.com
AUT00201 is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels. Safety and toxicology studies support the clinical development of AUT00201.
Autifony Therapeutics Ltd, Stevenage Bioscience Catalyst Reg. 07543962 Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX VAT. GB 325 4102 43
For more information, please contact:
Autifony Therapeutics Limited
Dr Charles Large, CEO
Tim Watson / Kiki Zaccagnini
T: +44 (0) 20 7457 2825
Copyright © 2023 Stevenage Bioscience Catalyst